Distribution and influencing factors of tumor mutational burden in different lymphoma subtypes.

e19053 Background: Tumor mutational burden (TMB) has emerged as a promising biomarker in melanoma, NSCLC, glioma, and likely across types of solid cancers. However, TMB distribution and influencing factors in non-Hodgkin's lymphoma are still unknown. Methods: In this study, we focused on tumor (tTMB) and peripheral blood TMB (bTMB) in different lymphoma subtypes and conducted a hybridization-capture methodology and targeted 1.1Mb or 1.7 Mb of genomic coding sequence. Analysis of 188 tumors and 98 plasma samples matching oral epithelial normal samples was performed to characterize the landscape of somatic mutations between the TMB high (TMB-H) and TMB low (TMB-L) groups. Results: In our cohort, tTMB and bTMB ranged from 0 to 42.48, and 0.59 to 37.17, respectively. The top quartile TMB distribution (tTMB:12.34, bTMB:13.20) was used as the cut-off value to define TMB-H. DLBCL had significantly higher tTMB than small B cell lymphoma and peripheral T-cell lymphoma (p < 0.0001). 34.09% of DLBCL had TMB-H, and minority of patients had TMB-H in small B cell lymphoma (3.70%), and peripheral T-cell lymphoma (3.85%). The bTMB had the similar distribution to tTMB. Among all the tumor and plasma samples we detected 8 gene mutations having a significant correlation with high TMB including BTG2, PIM1, DUSP2, HIST1H1E, BTG1, SOCS1, HIST1H1C, CD70 ( p< 0.05) . Table TMB distribution of different lymphoma subtypes Conclusions: Compared to other lymphoma subtypes, DLBCL had higher TMB. Particular gene mutation had correlation with high TMB.[Table: see text]

Download Full-text

Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma

Pathology International ◽

10.1111/j.1440-1827.2011.02713.x ◽

2011 ◽

Vol 61 (11) ◽

pp. 662-666 ◽

Cited By ~ 1

Author(s):

Sho Yamazaki ◽

Yosei Fujioka ◽

Fumihiko Nakamura ◽

Satoshi Ota ◽

Aya Shinozaki ◽

...

Keyword(s):

T Cell ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

T Cell Lymphoma ◽

Peripheral T Cell Lymphoma ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades--should peripheral T-cell lymphoma be considered separately?

Journal of Clinical Oncology ◽

10.1200/jco.1989.7.6.725 ◽

1989 ◽

Vol 7 (6) ◽

pp. 725-731 ◽

Cited By ~ 56

Author(s):

A L Cheng ◽

Y C Chen ◽

C H Wang ◽

I J Su ◽

H C Hsieh ◽

...

Keyword(s):

T Cell ◽

B Cell ◽

Induction Chemotherapy ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

T Cell Lymphoma ◽

High Grade ◽

Peripheral T Cell Lymphoma ◽

Laboratory Features ◽

Hodgkin's Lymphomas

Peripheral T-cell lymphoma (PTCL) forms a morphologically heterogeneous group of non-Hodgkin's lymphomas (NHL) with distinct immunophenotypes of mature T cells. Progress has been slow in defining specific clinicopathological entities to this particular group of NHL. In order to elucidate the specific characteristics of PTCL, a direct comparison of PTCL with a group of diffuse B-cell lymphomas (DBCL) was performed. Between June 1983 and December 1987, we studied 114 adults with NHL, using a battery of immunophenotyping markers. Adult T-cell leukemia/lymphoma, lymphoblastic lymphoma, mycosis fungoides/Sézary syndrome, follicular lymphoma, well-differentiated lymphocytic lymphoma, and true histiocytic lymphoma were excluded from this study since these are distinct clinicopathologic entities with well-recognized immunophenotypes. Of the remaining 75 patients, 70 who had adequate clinical information were analyzed, and of these, 34 were PTCL and 36 were DBCL. Classified according to the National Cancer Institute (NCI) Working Formulation (WF), 68% of PTCL and 31% of DBCL were high-grade lymphomas. Clinical and laboratory features were similar, except PTCL had a characteristic skin involvement and tended to present in more advanced stages with more constitutional symptoms. Induction chemotherapy was homogeneous in both groups, and complete remission rates were 62% for PTCL and 67% for DBCL. Patients with DBCL had a better overall survival than patients with PTCL, but the survival benefit disappeared after patients were stratified according to intermediate- or high-grade lymphoma. A subgroup of PTCL patients who had received less intensive induction chemotherapy was found to have a very unfavorable outcome. We conclude that (1) PTCL follows the general grading concept proposed in WF classification; (2) within a given intermediate or high grade, PTCL and DBCL respond comparably to treatment; (3) the intensity of induction chemotherapy has a crucial impact on the outcome of PTCL patients; and (4) with a few exceptions, the clinical and laboratory features of PTCL and DBCL are comparable.

Download Full-text

Epstein–Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma

International Journal of Hematology ◽

10.1007/s12185-008-0176-2 ◽

2008 ◽

Vol 88 (4) ◽

pp. 434-440 ◽

Cited By ~ 11

Author(s):

Katja C. Weisel ◽

Eckhart Weidmann ◽

Ioannis Anagnostopoulos ◽

Lothar Kanz ◽

Antonio Pezzutto ◽

...

Keyword(s):

T Cell ◽

B Cell ◽

Epstein Barr Virus ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

T Cell Lymphoma ◽

Peripheral T Cell Lymphoma ◽

Barr Virus ◽

Epstein Barr

Download Full-text

Lymphoma of the Uvula: Clinical, Morphological, Histopathological, and Genetic Characterization. A Nationwide Danish Study From 1980 to 2019

Frontiers in Surgery ◽

10.3389/fsurg.2021.675279 ◽

2021 ◽

Vol 8 ◽

Author(s):

Lars Iversen ◽

Patrick Rene Gerhard Eriksen ◽

Simon Andreasen ◽

Erik Clasen-Linde ◽

Preben Homøe ◽

...

Keyword(s):

T Cell ◽

B Cell ◽

Marginal Zone ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

T Cell Lymphoma ◽

B Cell Lymphomas ◽

Peripheral T Cell Lymphoma ◽

Presenting Symptoms ◽

Danish Study

Background: In the head and neck region the uvula is a rare site for extranodal lymphomas to develop. In this national study, we present six cases and provide an overview of the current literature, characterizing the clinical and histopathological features of lymphomas involving this location.Materials and Methods: Clinical information was obtained retrospectively from patient records in a nationwide Danish study covering from 1980 through 2019. In order to validate the diagnoses, uvular tissue specimens were examined histologically and immunohistochemically and if relevant for subtyping, cytogenetic rearrangements were investigated.Results: We present six cases of lymphomas involving the uvula, of which four of the cases were diagnosed with a B-cell lymphoma (two diffuse large B-cell lymphomas, one extranodal marginal zone B-cell lymphoma and one Mantle cell lymphoma), while two were diagnosed with a T-cell lymphoma (one peripheral T-cell lymphoma and one natural killer/T-cell lymphoma). Presenting symptoms included swelling, pain and ulceration of the uvula. Treatment was comprised of radiotherapy and/or chemotherapy, with T-cell lymphomas showing a poorer outcome than B-cell lymphomas.Conclusion: Lymphoma of the uvula is rare, with few case reports being reported in the literature. The most frequent histological subtypes reported are extranodal marginal zone B-cell lymphoma and peripheral T-cell lymphoma. When encountering a swollen, painful and/or ulcerated uvula, the clinician should always consider malignancy as a possible cause. Lymphoma of the uvula is a possible diagnosis and if this is the case, there is a high risk of disseminated disease at the time of diagnosis.

Download Full-text

Sequential development of large B cell lymphoma in a patient with peripheral T-cell lymphoma

Haematologica ◽

10.3324/haematol.11269 ◽

2008 ◽

Vol 93 (1) ◽

pp. e6-e8 ◽

Cited By ~ 5

Author(s):

A. Furlan ◽

F. Pietrogrande ◽

F. Marino ◽

C. Menin ◽

G. Polato ◽

...

Keyword(s):

T Cell ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

T Cell Lymphoma ◽

Peripheral T Cell Lymphoma ◽

Sequential Development ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

180 Sequential Development of Diffuse Large B-Cell Lymphoma in a Patient With Peripheral T-Cell Lymphoma: Challenges and Risk Factors

American Journal of Clinical Pathology ◽

10.1093/ajcp/aqx121.179 ◽

2018 ◽

Vol 149 (suppl_1) ◽

pp. S76-S77

Author(s):

Vanya Jaitly ◽

Natalia Golardi

Keyword(s):

Risk Factors ◽

T Cell ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

T Cell Lymphoma ◽

Peripheral T Cell Lymphoma ◽

Sequential Development ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Peripheral T-cell Lymphoma Following Diffuse Large B-cell Lymphoma Associated with Celiac Disease

Internal Medicine ◽

10.2169/internalmedicine.47.0500 ◽

2008 ◽

Vol 47 (4) ◽

pp. 295-298 ◽

Cited By ~ 6

Author(s):

Hideki Makishima ◽

Yuichi Komiyama ◽

Naoko Asano ◽

Kayoko Momose ◽

Shigeo Nakamura ◽

...

Keyword(s):

Celiac Disease ◽

T Cell ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

T Cell Lymphoma ◽

Peripheral T Cell Lymphoma ◽

Large B Cell Lymphoma ◽

Large B Cell

Download Full-text

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

Journal of Clinical Oncology ◽

10.1200/jco.2015.65.9789 ◽

2016 ◽

Vol 34 (23) ◽

pp. 2698-2704 ◽

Cited By ~ 493

Author(s):

Alexander M. Lesokhin ◽

Stephen M. Ansell ◽

Philippe Armand ◽

Emma C. Scott ◽

Ahmad Halwani ◽

...

Keyword(s):

Multiple Myeloma ◽

T Cell ◽

B Cell ◽

Cell Lymphoma ◽

B Cell Lymphoma ◽

T Cell Lymphoma ◽

Peripheral T Cell Lymphoma ◽

Large B Cell Lymphoma ◽

T Cell Lymphomas ◽

Large B Cell

Purpose Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint pathway to avoid immune surveillance by modulating T-lymphocyte activity. In part, this may occur through overexpression of PD-1 and PD-1 pathway ligands (PD-L1 and PD-L2) in the tumor microenvironment. PD-1 blockade has produced significant antitumor activity in solid tumors, and similar evidence has emerged in hematologic malignancies. Methods In this phase I, open-label, dose-escalation, cohort-expansion study, patients with relapsed or refractory B-cell lymphoma, T-cell lymphoma, and multiple myeloma received the anti–PD-1 monoclonal antibody nivolumab at doses of 1 or 3 mg/kg every 2 weeks. This study aimed to evaluate the safety and efficacy of nivolumab and to assess PD-L1/PD-L2 locus integrity and protein expression. Results Eighty-one patients were treated (follicular lymphoma, n = 10; diffuse large B-cell lymphoma, n = 11; other B-cell lymphomas, n = 10; mycosis fungoides, n = 13; peripheral T-cell lymphoma, n = 5; other T-cell lymphomas, n = 5; multiple myeloma, n = 27). Patients had received a median of three (range, one to 12) prior systemic treatments. Drug-related adverse events occurred in 51 (63%) patients, and most were grade 1 or 2. Objective response rates were 40%, 36%, 15%, and 40% among patients with follicular lymphoma, diffuse large B-cell lymphoma, mycosis fungoides, and peripheral T-cell lymphoma, respectively. Median time of follow-up observation was 66.6 weeks (range, 1.6 to 132.0+ weeks). Durations of response in individual patients ranged from 6.0 to 81.6+ weeks. Conclusion Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients with relapsed or refractory B- and T-cell lymphomas. Additional studies of nivolumab in these diseases are ongoing.

Download Full-text